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A B S T R A C T
Background: L-Homocysteine (Hcy) is a non-proteinogenic α-amino acid synthesized from dietary methionine. In
healthy humans, high Hcy levels are a risk factor for cardiovascular diseases, stroke and type 2 diabetes. A recent
study reports that Hcy reacts with Cys10 of transthyretin (TTR), generating a stable covalent adduct. However, to
date the effect of S-homocysteinylation on TTR conformational stability remains unknown.
Methods: The effect of Hcy on the conformational properties of wt- and L55P-TTR were analysed using a set of
biophysical techniques. The cytotoxicity of S-homocysteinylated L55P-TTR was also evaluated in the HL-1
cardiomyocyte cell line, while the effects of the assemblies on kinematic and dynamics properties of cardiac
muscle cells were analysed in cardiomyocyte syncytia.
Results: We found that Hcy stabilizes tetrameric wt-TTR, while it destabilizes the tetrameric structure of the
L55P mutant, promoting the accumulation of self-assembly-prone monomeric species.
Conclusions: Our study demonstrated that S-homocysteinylation of the L55P-TTR mutant impairs protein sta-
bility, favouring the appearance of toxic monomers. Interestingly, S-homocysteinylation affected only mutant,
not wt-TTR. Moreover, we also show that assemblies of S-homocysteinylated L55P-TTR impair cardiomyocytes
functional parameters.
General significance: Our study offers new insights on the negative impact of S-homocysteinylation on L55P-TTR
stability, whose aggregation is considered the causative agent of a form of early-onset familial amyloid poly-
neuropathy and cardiomyopathy. Our results suggest that high homocysteine levels are a further risk factor for
TTR cardiomyopathy in patients harbouring the L55P-TTR mutation.
1. Introduction
Hyperhomocysteinemia is a risk factor for cardiovascular disease
and neurodegenerative disorders [1]. In the body fluids, free homo-
cysteine (Hcy) accounts for only 2% of total Hcy while about 70–80% of
Hcy is covalently bound to proteins. The remaining 20% of Hcy exists as
both low-molecular-weight disulfides (homocystine) and Hcy-cysteine
mixed disulfides [2–4]. Hcy binds covalently to free protein cysteine
residues or cleaves accessible cysteine disulfide bonds (S-homo-
cysteinylation) altering protein molecular structure and/or function
[4,5]. Recently, several S-homocysteinylated proteins have been iden-
tified and the functional consequences of this covalent modification are
starting to emerge. It has been proposed that protein homocysteinyla-
tion, rather than free Hcy, triggers cell responses related to up-regula-
tion of effectors involved in vascular remodelling and in the patho-
genesis of atherosclerotic lesions [6]. For instance, an in vitro study
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reported that annexin II S-homocysteinylation at Cys8, hinders the
specific interaction between tissue plasminogen activator and en-
dothelial cell surface [7]. Moreover, it has been reported that homo-
cysteinylation impairs inactivation of factor Va by activated protein C
[8] and that the activation by Hcy of latent elastolytic metalloprotei-
nase pro-MMP-2 could be one of the initial events that contribute to
elastin alteration in patients affected by hyperhomocysteinemia [9].
Other findings indicate that Hcy in vitro interacts with fibronectin,
thereby inhibiting its binding to fibrin [10], and that apolipoprotein
homocysteinylation results in antiangiogenic and pro-atherogenic ef-
fects [11]. Finally, it has been reported that S-homocysteinylation
causes the inactivation of metallothionein, a ubiquitous intracellular
zinc-chaperone and superoxide anion radical scavenger, suggesting a
novel mechanism for disruption of intracellular zinc and redox home-
ostasis [12]. Taken together, these findings suggest that protein
homocysteinylation may affect multiple cellular pathways with im-
portant functional consequences.
Transthyretin (prealbumin) is a 55.2 kDa protein synthesized pre-
dominantly in the liver and choroid plexi and secreted into the plasma
and CSF, respectively. As a homotetramer, transthyretin binds and
transports thyroxine and the retinol-binding protein-retinal complex
[13]. Familial amyloid polyneuropathy/cardiomyopathy (FAP/FAC)
and senile systemic amyloidosis (SSA) are pathological conditions as-
sociated to the extracellular deposition of amyloid aggregates of mutant
or wild type TTR, respectively, even though SSA in some cases may also
be genetically determined [14,15]. Polyneuropathy and cardiomyo-
pathy are predominant signs of most TTR amyloidosis, whose most
severe cases can be treated only by liver and, possibly, heart trans-
plantation.
Generally, the most severe early onset TTR amyloidosis are asso-
ciated to TTR variants (V122I, V30G, and L55P) whose tetrameric na-
tive state is remarkably destabilized. In these cases, mutation favours
tetramer dissociation and the accumulation of monomers/dimers self-
associating into amyloid intermediates and mature fibrils [16]. Pre-
sently, TTR tetramer dissociation is recognized as the rate-limiting step
of amyloid fibril nucleation and growth.
Each TTR monomer contains a single cysteine residue at position 10
(Cys10). In the folded tetrameric protein, the four Cys10 residues occupy
exposed sites at the beginning of the helical regions and can react with
free cysteine and other sulfur-containing ligands [17], including Hcy
[18]. Recently, the TTR-Cys10–S–S–Hcy adduct was identified by im-
munoprecipitation and HPLC/MS analysis in the plasma of patients
with end-stage renal disease or affected by homocystinuria [19,20]. The
TTR-Cys10–S–S–Hcy/unmodified TTR ratio increases with increasing
plasma concentration of Hcy, suggesting that an Hcy burden can affect
the plasma levels of TTR-Cys10–S–S–Hcy. To date, the functional, bio-
chemical and pathological consequences of TTR S-homocysteinylation
have not been completely assessed.
2. Material and methods
2.1. TTR samples
Recombinant wt-TTR and L55P-TTR were expressed and purified
according to Mangione et al. [21,40]. Lyophilized wt-TTR and L55P-
TTR were dissolved at 1.6 mM in 30mM sodium phosphate buffer,
pH 7.0. wt-TTR and L55P-TTR were diluted at 50 μM final concentra-
tion in the same buffer and incubated at 37 °C for up to 96 h either alone
or in the presence of Hcy in a 1:2 TTR tetramer: Hcy molar ratio.
2.2. Growth of toxic HypF-N oligomers
HypF-N was expressed in E. coli and purified by an affinity chro-
matography column packed with the HIS-Select Nickel Affinity Gel
(Sigma-Aldrich, St. Louis, MO, USA), as previously described [22,23].
The purified native protein was stored at −80 °C in 20mM Tris-HCl
buffer, pH 8.0, containing 2.0 mm dithiothreitol (DTT) and used as a
control (native HypF-N). Toxic HypF-N oligomers were grown by in-
cubating the native protein (48 μM) for 4 h at 25 °C in 50mM acetate
buffer, pH 5.5, containing 12% (v/v) trifluoroethanol (TFE), 2.0 mM
DTT. The oligomers were collected by centrifugation at 16,000g for
10min, dried under N2, and suspended to a final concentration of
12 μM in cell culture medium for cell biology tests.
2.3. TTR Digestion
20 μg protein (wt-TTR; L55P-TTR; wt-TTR-S-Hcy; L55P-TTR-S-Hcy)
were dissolved in 50 μL of 50mM ammonium bicarbonate, pH 8.5,
containing 6.0M urea, incubated for 5min in a boiling water bath and
then chilled in ice. Then, 0,5 μg of trypsin was added to the samples
following dilution with 50mM ammonium bicarbonate, pH 8.5 (5 vol.).
After 2 h incubation at 37 °C, the reaction was stopped by adding
Trifluoroacetic acid (TFA) (0.1% final concentration). Then, the pep-
tides were desalted and purified by using Zip-Tip C18, according to the
manufacturer's protocol. To assess the right interpretation of the results,
aliquots of each protein sample were reduced and alkylated prior to
proteolytic digestion. Briefly, after the denaturation step, the proteins
were treated with 20mM DTT at 60 °C. After 30min, Indoleacetic acid
(IAA) (55mM final concentration) was added; the samples were in-
cubated at R.T. in the dark for 30min and then added with DTT (20mM
final concentration).
2.4. MS Analysis
Peptide mass fingerprints were analysed with a MALDI-TOF/TOF
mass spectrometer Ultraflex III (Bruker Daltonics, Bremen, Germany)
by using Flex Control 3.0 as data acquisition software. A 0.75 μL sample
volume was mixed with 0.75 μL of the matrix (saturated solution of α-
cyano-4-hydroxycinnamic acid in 50% (v/v) acetonitrile and 0.5% (v/
v) TFA) on the anchorchip target plate and allowed to dry. The spectra
were acquired in reflectron mode in the 860–4000m/z range, for 500
shots. The instrumental parameters were chosen by setting the ion
source 1 at 25 kV, ion source 2 at 21.5 kV, the pulsed ion extraction at
20 ns and the detector gain at 7.7×. The instrument was externally
calibrated prior to analysis using the Bruker Peptide Calibration stan-
dard kit. The spectra were processed and annotated by the Flex Analysis
3,0 software. Peptide mass finger prints were interpreted using the
BioTools 3,2 and the Sequence Editor software (Bruker Daltonics).
Digestion results were compared with the theoretical ones obtained by
virtual digestion of wt-TTR or L55P-TTR. The parameters used were:
trypsin as cleaving enzyme, allowing three missed cleavages, and
50 p.p.m. mass tolerance. Reduced cysteine, carbamidomethyl cysteine
(CAM-C) or homocysteinyl-cysteine (Hcys-C) was alternatively set as a
fixed modification.
2.5. SDS-PAGE
Proteins were separated by SDS-PAGE. The samples were dissolved
in Laemmli sample buffer (62.5mM Tris-HCl buffer, pH 6.8, 2.0% SDS,
25% glycerol, 0.01% bromphenol blue). 0.1% β-mercaptoethanol
(BME) was added before sample boiling in a water bath (10min, 95 °C).
Then, 10 μL samples were applied onto the 15% SDS-PAGE gel. The
bands were visualized by Coomassie Brilliant Blue. SDS-PAGE was
performed three times.
2.6. Native-PAGE
“Native” or “non-denaturing” gel electrophoresis was run in the
absence of SDS. Running Buffer 5×, Leammli 2× and 12% acrylamide
gel without SDS were used. The samples were not boiled and were
dissolved in Laemmli sample buffer without SDS. The bands were vi-
sualized by Coomassie Brilliant Blue. Native-PAGE was performed three
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times.
2.7. Fourier transform infrared (FTIR) spectroscopy
The FTIR spectra of the different samples were collected in atte-
nuated total reflection (ATR) at a protein concentration of 20 μM (in
30mM sodium phosphate buffer pH 7.0) in the absence or in the pre-
sence of Hcy (1:2 ratio). In particular, 3 μL sample aliquots were de-
posed on the ATR diamond plate (Golden Gate, Specac, UK) and the
spectra were acquired after solvent evaporation, as previously de-
scribed [24,25]. A Varian 670-IR spectrometer (Varian Australia) was
employed under the following conditions: 2.0 cm−1 spectral resolution,
25 kHz scan speed, 1000 scan coadditions, and triangular apodization.
The second derivatives of the measured spectra were obtained after
Savitsky-Golay smoothing by the Resolutions-Pro software (Varian
Australia).
2.8. Turbidimetry
The propensity of L55P-TTR to aggregate was monitored by turbi-
dimetry. The aggregation process was measured by spectrophotometry
as the increase in the apparent absorbance value. Aggregate growth
results in the formation of a cloudy suspension that scatters the light
reducing its passage through the sample. According to the method
previously reported [26] we monitored sample turbidity in a 96 mul-
tiwell plate containing 5.0 μM L55P-TTR alone or in the presence of
10 μM Hcy (1:2molar ratio) in sodium phosphate buffer, pH 7.0, at
37 °C without stirring. Sample absorbance was determined at 400 nm
with an automatic plate reader (Bio-Rad).
2.9. HPLC analysis
HPLC analysis of wt-TTR and L55P-TTR samples incubated in the
absence or in the presence of Hcy for 24 h was performed by a DIONEX
P680-UVD170U system after centrifugation at 14000 rpm for 30min at
4 °C. Sample chromatographic resolution was achieved on a
300×7.80mm, 5.0 μm, BioSep-SEC-S 3000 column (Phenomenex)
using 100mM sodium chloride in 30mM phosphate buffer, pH 7.0 at a
flow rate of 0.5mL/min. 50 μL sample injection volume was used;
sample detection was based on UV absorbance at 280 nm.
2.10. Transmission electron microscopy
5.0 μL aliquots of L55P-TTR incubated in the absence or in the
presence of Hcy were withdrawn at different incubation times, loaded
onto a formvar/carbon-coated 400 mesh nickel grids (Agar Scientific,
Stansted, UK) and negatively stained with 2.0% (w/v) uranyl acetate
(Sigma-Aldrich). The grid was air-dried and examined using a JEM
1010 transmission electron microscope at 80 kV excitation voltage.
2.11. Circular dichroism spectroscopy
The spectra of wt-TTR (5.0 μM in 30mM sodium phosphate buffer
pH 7.0) were recorded in the absence or in the presence of Hcy (1:2
ratio) using a Jasco J-810 spectropolarimeter equipped with a ther-
mostated cell holder attached to a Thermo Haake C25P water bath. The
spectra were acquired with a 2.0 cm/min can speed and data points
were collected in the 260–190 nm interval at 25 °C with a 1.0mm path
length quartz cell. All spectra were blank-subtracted and converted to
molar ellipticity per residue.
2.12. Dynamic light scattering (DLS)
DLS measurements were performed using a ZetasizerNano S DLS
device from Malvern Instruments (Malvern, Worcestershire, UK), ther-
mostated with a Peltier system using a low-volume (45 μL) ultramicro
cell (Hellma Analytics, Müllheim, Germany). wt-TTR and L55P-TTR
incubated in the absence or in the presence of Hcy for different lengths
of time, were centrifuged for 30min at 4 °C and 14,000 rpm, to pre-
cipitate the largest aggregates. Size distributions by intensity and vo-
lume were determined at regular time-intervals over a period of 10min.
The temperature was maintained at 37 °C and the parameters were set
manually on the instrument to allow the same settings in the various
distributions acquired at different times. These included ten 10 s ac-
quisitions with cell position 4.2 cm and attenuator index 7. The re-
ported data are the average of three consecutive measurements.
2.13. Resveratrol binding assay
The fluorescence studies were based on the method reported by
Florio and co-workers [27]. Briefly, resveratrol was excited at 320 nm
and the emission spectra were recorded in the 350–450 nm range. Free
resveratrol displays maximum fluorescence at 390 nm. Fluorescence
intensity increased substantially upon binding to TTR. All data were
obtained in the presence of 5.0 μM wt-TTR and L55P-TTR in 30mM
sodium phosphate buffer, pH 7.0 alone or pre-incubated with 10 μM
Hcy. At different incubation times, sample aliquots were withdrawn
and mixed with 10 μM resveratrol for analysis.
2.14. Isolation and culture of HL-1 cardiomyocytes
HL-1 mouse atrial myocytes were obtained from Dr. W. C. Claycomb
(Louisiana State University Health Science Center, New Orleans, LA,
USA) and grown in T25, gelatin- fibronectin coated flasks, as previously
described [28]. The cells were maintained in Claycomb Medium (JRH
Biosciences), supplemented with 10% foetal bovine serum (Sigma-Al-
drich), 2.0 mM L-glutamine (Sigma-Aldrich), 0.1 mM noradrenaline
(Sigma-Aldrich) and 100 U/mL penicillin-streptomycin (Sigma-Al-
drich). Every three days the cells were detached and re-plated at a 1:3
dilution in a new T25 flask or in 96 well plates (70–90% confluent) and
used for experimental measurements.
2.15. MTT assay
The MTT assay, used to assess cell viability, was optimized for the
cell lines used in the experiments. Briefly, HL-1 cells were seeded into
96-well plates at a density of 6000 cells/well in fresh complete medium
and grown for 48 h. Then, the cells were treated for 24 h with 5.0 μM
L55P-TTR (tetramer) at different times of aggregation in the presence or
in the absence of Hcy (10 μM). To analyse protection by L55P-TTR-S-
Hcy, HypF-N oligomers (12 μM monomer concentration) were shacked
in the cell culture media for 1 h at 37 °C, either alone or in the presence
of L55P-TTR or L55P-TTR-S-Hcy, at a HypF-N:TTR molar ratio of 10:1.
L55P-TTR-S-Hcy was obtained by incubating the protein with or
without Hcy for 30min and 96 h. Each sample was added to the cell
culture medium for 24 h; then, the medium was removed and the cells
were incubated for 1 h at 37 °C with 100 μL of serum-free DMEM
without phenol red, containing 0.5mg/mL MTT. At the end of the in-
cubation, 100 μL of cell lysis solution (20% SDS, 50% N,N-di-
methylformamide) was added to each well and the samples were in-
cubated at 37 °C to allow complete lysis. The absorbance of the blue
formazan was read automatically at 570 nm using a spectrophotometric
microplate reader. The final absorption values were calculated by
averaging each sample in triplicate and subtracting from this the
average of the blank, (a mixture of 100 μL of MTT solution and 100 μL
of lysis solution).
2.16. Intracellular calcium flux
Briefly, HL-1 cells were cultured in an 8-well Lab-Tek II Chamber
slide system (Thermo-Fisher) in complete medium containing 10% FBS.
After 48 h, the cells were loaded for 10min with FLUO-3 AM
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(Invitrogen, Inc.), a fluorescent cell Ca2+ indicator. Then, the L55P-TTR
samples obtained by incubation for different times with Hcy (1:2 molar
ratio) were added to the medium at 5.0 μM final concentration. Cell
fluorescence was imaged using a confocal Leica TCS SP5 scanning
microscope (Leica, Mannheim, Ge) equipped with a HeNe/Ar laser
source for fluorescence measurements. The observations were per-
formed using a Leica Plan 7 Apo X63 oil immersion objective, suited
with optics for DIC acquisition. For image acquisition, an exposure time
Fig. 1. Mass Spectra of tryptic digests from homocysteinylated wt-TTR and L55P-TTR. (A) wt-TTR and (B) L55P-TTR pre-incubated with Hcy were digested with
trypsin and the obtained peptide mixtures were analysed by MALDI-TOF/TOF. The experimental peptide mass finger prints were compared with the theoretical ones
obtained by the virtual digestion of wt-TTR or L55P-TTR containing homocysteinylated cysteine 10. The sequence analysis results are under each mass spectrum. The
(C) and (D) panels show the mass spectra and the sequence analysis of the tryptic digests from wt-TTR (C) and L55P-TTR (D) reduced and alkylated with carba-
midomethyl-cysteine prior to digestion. * Homocysteinylated Cysteine; ° Carbamidomethylated Cysteine.
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of 30 s was used for a total time of 5 h. Cells from three independent
experiments and three areas (about 20 cells/area) per experiment were
analysed. The fluorescence intensity of Fluo3-AM was analysed by using
ImageJ software (National Institutes of Health Bethesda, MD), and ex-
pressed as arbitrary units.
2.17. Embryonic stem cell culture and differentiation into cardiomyocytes
R1 mouse embryonic stem cell line (mESCs; kindly provided by Dr.
Nagy from Samuel Lunenfeld Research Institute, Mount Sinai Hospital,
Toronto, Ontario, Canada) was cultured as reported in [29]. Briefly, R1
mESCs were maintained in Knockout DMEM, added with 15% ESC
Qualified FBS (Gibco), 2.0mM L-glutamine, 1× non-essential amino
acids, 0.5% penicillin/streptomycin (all from Thermo Fisher Scientific),
0.1 mM β-mercaptoethanol (Sigma) and 500 U/mL ESGRO-Leukemia
Inhibitory Factor (LIF; Merck Millipore, Italy). The STO cell line (ATCC
CRL-2225), used as feeder layer for mESCs, was maintained in DMEM
(Sigma) supplemented with 10% foetal bovine serum, 4.0mM L-gluta-
mine, 0.5% penicillin–streptomycin solution (all from Thermo Fisher
Scientific), 0.1 mM β-mercaptoethanol (Sigma) and 0.2 mg/mL genet-
icin (Sigma). The cells were maintained at 37 °C with 5% CO2 in air.
mESCs were induced to differentiate in vitro by removing the LIF from
the culture medium and through the formation of embryoid bodies
(EBs), using the hanging drop method [30,31]. For EBs formation, 20 μL
droplets of culture medium containing 103 mESCs were plated on the
lid of p55 Petri dish. On day 3 of culture, the developing EBs were
transferred to 0.1% agarose-coated dishes (Corning) and from day 5,
about 25 EBs were plated onto 22mm gelatin-coated Glass Bottom
Dishes (WillCo Wells) and cultivated up to day 15.
2.18. Treatment with L55P-TTR and L55P-TTR-S-Hcy, video acquisition
and processing for kinematic and dynamics properties evaluation
At the end of the differentiation process (day 15), the cells were
exposed for 24 h to 5.0 μM L55P-TTR incubated 96 h in sodium phos-
phate buffer, pH 7.0, in the absence or in the presence of 10 μM Hcy
(1:2 molar ratio). On day 16, the glass bottom dishes with beating
cardiomyocyte syncytia were transferred into the culture chamber of
the Nikon BioStation IM at 37 °C and 5% CO2. AVI videos were recorded
from ten randomly chosen untreated or treated beating syncytia with
the Snagit software and processed as previously described [32]. This
procedure was repeated for three independent experiments.
2.19. Statistical analysis
Analysis of the data was performed by using T-student test to de-
termine differences in cytotoxicity. The syncytium contractile proper-
ties are expressed as mean ± 95% confidence interval for the differ-
ences between means and the data were analysed by the one-way
ANOVA and by the post hoc LSD test.
3. Results
Hcy levels are typically higher in men than in women and increase
with age; normal serum levels of total Hcy are in the 4.0–15 μM range
[33] and concentrations above 15 μM are considered dangerous. Taking
into account that only 2% of total Hcy is present in plasma as reduced
form, we sought to test the effects of pathological concentration of
soluble Hcy (10 μM) on stability and aggregation propensity of wt-TTR
and the highly destabilized mutant L55P-TTR.
3.1. S-Homocysteinylation of wt-TTR and L55P-TTR
Homocysteinylation of wt-TTR and L55P-TTR was obtained by in-
cubating either protein for 24 h in the presence of 10 μMHcy; the extent
of S-homocysteinylation was assessed by sample digestion with trypsin
and subsequent analysis by MALDI-TOF (Fig. 1). The experimental
[M+H+] peak list generated for each protein was compared with the
theoretical [M+H+] peak list generated by “in silico” digestion of wt-
TTR and L55P-TTR, by setting Cys-S-homocysteinylation as variable
modification. The results confirmed that the tryptic digests from both
proteins contain peptides with a molecular weight compatible with that
of Cys10-homocysteinylated peptides (Fig. 1A, B). In both cases, we did
not identify the [M+H+] peaks putatively derived from the un-
modified (reduced) proteins nor disulfide bridge-containing peptides.
To confirm the validity of our results, we also analysed the tryptic di-
gests of the homocysteinylated proteins preliminarily reduced and al-
kylated with carbamidomethyl-cysteine (Fig. 1 C, D). The spectra
missed the [M+H+] homocysteinylated peptides signals while showed
the [M+H+] peaks corresponding to carbamidomethyl peptides.
3.2. S-Homocysteinylation stabilizes the native conformation of wt-TTR
The effect of S-homocysteinylation on the structural features of wt-
TTR (1:2; tetrameric wt-TTR:Hcy molar ratio) was analysed by native-
and SDS-PAGE, resveratrol binding, circular dichroism (CD), Fourier-
transform infrared (FTIR) spectroscopy, gel filtration and dynamic light
scattering (DLS). Electrophoretic analysis under native conditions
showed that following incubation of wt-TTR with Hcy the relative
amount of tetrameric TTR increased (Fig. 2A). Similar results were
obtained analysing the same sample in a SDS-PAGE system. The wt-TTR
sample displayed two bands (monomer and dimer) whose extent ap-
parently decreased in the sample incubated with Hcy, with the ap-
pearance of a new, 55 kDa, band corresponding to the tetramer. Inter-
estingly, we observed that the band corresponding to TTR tetramer
disappeared in the presence of 0.1% BME, a reducing agent (Fig. 2B).
This evidence suggested that reaction of Hcy with Cys10 residue of TTR
favours stabilization of TTR tetramer, which was almost completely lost
when Hcy was displaced by BME.
t-Resveratrol (t-Res) is a polyphenol known to bind and to stabilize
the wt-TTR tetramer. We evaluated t-Res binding to wt-TTR using a
spectrofluorimeter. When excited at 320 nm, t-Res displays a specific
emission spectrum with a maximum fluorescence peak around 390 nm
that is enhanced upon binding to wt-TTR tetramer [27]. Using this
binding assay, we observed that S-homocysteinylated wt-TTR main-
tained the same ability to bind t-Res as the unmodified protein, sug-
gesting that S-homocysteinylation did not alter the polyphenol binding
to wt TTR (Fig. 2C).
We next investigated whether TTR S-homocysteinylation altered the
size and the structure of tetrameric TTR. DLS analysis revealed that
both wt-TTR and wt-TTR-S-Hcy incubated at pH 7.0 up to 24 h showed
an apparent hydrodynamic diameter (Dh) of about 6.0 nm, consistent
with that of the tetrameric structure of native TTR (Fig. 2D) [34].
Moreover, CD analysis did not reveal any significant change of sec-
ondary structure in homocysteinylated wt-TTR (Fig. 2E). The content of
secondary structure in wt-TTR and wt-TTR-S-Hcy was also assessed by
Amide I band analysis (1700–1600 cm−1) in the protein FTIR spectra
(Fig. 2F). As previously reported [24,25], the second derivative of the
absorption spectrum of wt-TTR was dominated by a component around
1630 cm−1, assigned to native β-sheet structure (Fig. 2F). Additional
components were also observed in the spectrum, whose assignments to
protein native secondary structures are indicated in Fig. 2F [24,25]. No
significant conformational changes were detected in wt-TTR-S-Hcy by
FTIR spectroscopy (Fig. 2F). Finally, we did not detect any difference
between wt-TTR and wt-TTR-S-Hcy retention times in gel filtration
analysis (Fig. 2G). Taken together, our biophysical data suggest that S-
homocysteinylation does not induce any structural modification of the
tetrameric fold in wt-TTR as confirmed also by SDS-PAGE of wt-TTR
incubated with Hcy for 96 h (Fig. 2H).
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3.3. S-Homocysteinylation destabilizes the L55P-TTR tetrameric fold
Based on results reported above, we wondered whether S-homo-
cysteinylation produced similar effects on the L55P-TTR mutant. We
preliminarily showed by mass spectrometry the presence of a dis-
ulphide bridge between Hcy and the Cys10 residue of L55P-TTR
(Fig. 1B, D). When we checked the ability to interact with t-Res, we
found that, contrary to wt-TTR-S-Hcy, L55P-TTR-S-Hcy did not bind the
polyphenol (Fig. 3A), indicating destabilization of the tetrameric
structure even after 30min of incubation with Hcy. Moreover, gel fil-
tration analysis showed that the soluble protein content was sig-
nificantly reduced in samples containing L55P-TTR and Hcy, suggesting
Fig. 2. Effects of wt-TTR S-homocysteinylation. (A) Native and (B) SDS-PAGE of wt-TTR and wt-TTR-S-Hcy. (C) t-Res binding assay to wt-TTR and wt-TTR-S-Hcy. (D)
Dynamic Light Scattering of wt-TTR and wt-TTR-S-Hcy. (E) CD spectra of wt-TTR (solid black line) and wt-TTR-S-Hcy (dashed black line). (F) Second derivatives of
the FTIR absorption spectra of wt-TTR (solid black line) and wt-TTR-S-Hcy (dashed line). The peak assignments to the protein secondary structures are reported. (G)
GF-HPLC analyses of wt-TTR and wt-TTR-S-Hcy obtained after 24 h of incubation in sodium phosphate buffer, pH 7.0 at 37 °C. (H) SDS-PAGE of wt-TTR and wt-TTR-
S-Hcy after 96 h of incubation with Hcy. The data shown are representative of three independent experiments.
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Fig. 3. Size distribution and resveratrol binding
assay of L55P-TTR and L55P-TTR-S-Hcy. (A)
Resveratrol binding assay of L55P-TTR and
L55P-TTR-S-Hcy at pH 7.0 at the two different
incubation times. (B) GF-HPLC analyses of L55P-
TTR and L55P-TTR-S-Hcy obtained by incuba-
tion for 24 h in sodium phosphate buffer, pH 7.0,
at 37 °C. (C) Apparent Hydrodynamic diameter
values observed in the same samples analysed
by DLS at two different incubation times Size
distribution over time of L55P-TTR and L55P-
TTR-S-Hcy at pH 7.0 as shown by DLS intensity
spectra (D) and volume spectra (E). (F) Second
derivatives of the absorption spectra of L55P-
TTR (solid black line) and of L55P-TTR-S-Hcy
(dashed line). The peak assignments to the pro-
tein secondary structures are reported. (G)
Native-PAGE (left) and SDS-PAGE (right) L55P-
TTR and of L55P-TTR-S-Hcy after 96 h of in-
cubation without and with Hcy, respectively.
The data shown are representative of three in-
dependent experiments.
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that L55P-TTR is destabilized by Hcy (Fig. 3B). DLS analysis confirmed
this hypothesis. In fact, we found that 30min incubation of L55P-TTR
with Hcy resulted in a population of particles with Dh of about 6.0 nm, a
value consistent with the apparent hydrodynamic diameter of the tet-
rameric protein (Fig. 3C–E). However, after 96 h of incubation, L55P-
TTR appeared still homogeneously composed of particles of about
6.0 nm Dh while the L55P-TTR-S-Hcy sample was populated of particles
of larger Dh, corresponding to protein aggregates (Fig. 3C–E). Overall,
these data suggest that, contrary to wt-TTR, S-homocysteinylation of
L55P-TTR results in tetramer destabilization favouring the appearance
of aggregation-prone low molecular weight species eventually resulting
in the appearance of self-assembled large assemblies.
The FTIR spectra of both L55P-TTR-S-Hcy and L55P-TTR were
found to be dominated by a component at 1630 cm-1 and did not reveal
any significant conformational change between the two samples. These
data indicated that the S-homocysteinylation of L55P-TTR destabilized
the tetrameric structure of the protein, confirming the t-Res assay. In
addition, the absence of new peaks at around 1615 cm−1 or 1682 cm−1
(typical signatures of intermolecular β-sheets in protein aggregate)
suggested that the S-homocysteinylation induced the appearance of
aggregation-prone low molecular weight species without promoting
amyloid formation (Fig. 3F). The tetrameric destabilization induced by
Hcy presence is confirmed by Native- and SDS-PAGE of L55P-TTR
(Fig. 3G).
3.4. Conformational properties of homocysteinylated L55P-TTR
We also analysed aggregation of L55P-TTR and L55P-TTR-S-Hcy by
turbidity assay (Fig. 4A). At each incubation time, the L55P-TTR-S-Hcy
complex displayed higher turbidity than L55P-TTR, suggesting that S-
homocysteinylation increased the amount of higher molecular weight
species in the sample. We also observed the morphology of L55P-TTR
and L55P-TTR-S-Hcy samples by transmission electron microscopy
(TEM). At each time (data not shown), after 96 h of incubation with Hcy
the covalently modified TTR produced a larger amount of aggregated
structures on the formvar dish than the unmodified protein (Fig. 4B).
3.5. Hcy induces dissociation of L55P-TTR, protecting HL-1 cells from toxic
effect of HypF oligomers
It was previously reported that human cerebrospinal fluid (CSF)
inhibited Aβ40 aggregation into amyloid fibrils in vitro [35] and that
TTR was responsible of this effect due to its ability to form stable
complexes with misfolded Aβ40 [36]. Recently, it has been observed
that TTR can suppress the toxicity of extracellularly added oligomers
formed by two different peptides/proteins, Aβ42 and HypF-N [23,37].
In particular, an engineered, stable monomeric derivative of human
TTR with intrinsic stability (M-TTR) engineered by introducing two
methionine substitutions (F87M and L110M) displayed disarranged
subunit interfaces of the tetramer, which resulted in protection of SH-
SY5Y cells and rat primary neurons against oligomer-induced cyto-
toxicity [37]. Moreover, the interaction between HypF-N/Aβ42 oligo-
mers and M-TTR was found to involve oligomer clustering [36]. Based
on these data we performed an MTT assay to assess the presence of
monomeric species in the destabilized tetramer of L55P-TTR-S-Hcy
sample. In particular, L55P-TTR (5.0 μM) was incubated with homo-
cysteine (10 μM) for different lengths of time (30min and96 h); then,
each sample, was diluted to 1.2 μM final concentrationin cultured cell
medium containing 12 μM HypF oligomers for 1 h; murine cardio-
myocytes (HL-1) were treated for 24 h with these samples; this cell line
was chosen since it is susceptible to TTR amyloid cytotoxicity (Fig. 4D)
[24]. Other cells were treated for 24 h with HypF oligomers, previously
treated in cell medium without or with M-TTR (1.2 μM). Fig. 4D shows
that, under these conditions, L55P-TTR and L55P-TTR-S-Hcy were not
toxic to HL-1 cells whereas about a 50 and 40% of reduction in cell
viability upon exposure to HypF oligomers or M-TTR, respectively, was
observed, in agreement with previous data [23]. However, when HL-1
cells were incubated with HypF oligomers previously treated with
L55P-TTR, a 20% increase of viability was observed regardless of L55P-
TTR aging time; moreover, when the cells were incubated for 24 h with
HypF oligomers pre-treated with L55P-TTR-S-Hcy aged 30min or 96 h,
a 20% and a complete recovery of cell viability, respectively, was ob-
served. A similar effect was seen also, when we used HypF oligomers
pre-treated with M-TTR (Fig. 4D). This result indicates that L55P-TTR-
S-Hcy, particularly the L55P-TTR-S-Hcy 96 h, behaves similarly to
chaperonic M-TTR, suggesting that in the L55P-TTR-S-Hcy 96 h sample,
a significant amount of monomeric TTR, sufficient to bind and to sup-
press HypF-N oligomers toxicity, is present.
3.6. Homocysteinylation increases L55P cytotoxicity
Once assessed the effect of S-homocysteinylation on L55P-TTR sta-
bility we tested L55P-TTR-S-Hcy cytotoxicity to HL-1 cells by the MTT
assay. The cells were treated for 24 h with 5.0 μM of L55P samples in-
cubated in vitro for different times at pH 7.0 in the presence or in the
absence of Hcy. The MTT assay showed that all L55P-TTR samples
obtained in the absence of Hcy induced a similar toxicity (about 10%),
whereas only the L55P-TTR–S-Hcy sample aggregated 96 h induced a
significantly higher cell sufferance (about 35%) (Fig. 5A). Confocal
analysis on living cells using Fluo-3 AM, a dye that binds intracellular
free Ca2+, showed that cell exposure to L55P-TTR incubated for 96 h
with Hcy resulted in a significant and biphasic (peaks at 30min and
60min) increase of intracellular free Ca2+, which may result in cyto-
toxic event as observed by the MTT assay results (Fig. 5 A, B, C).
3.7. Effects of L55P-TTR and L55P-TTR-S-Hcy on kinematics contractile
properties of cardiomyocyte syncytia
We also sought to determine some functional correlates to the cy-
totoxic effects assessed by the MTT assay carried out on HL-1 cells by
checking the contractile properties of cardiac syncytia differentiated
from mouse embryonic stem cells [31]. To this aim, the syncytia were
exposed for 24 h to 5 μM L55P-TTR or to L55P-TTR-S-Hcy aged 96 h. On
recorded AVI videos, chronotropic (beat frequency [Hz]), inotropic
(contractility [pixel/s], contraction force [pixel/s2]) and ergotropic
(consumption of ATP for kinetic energy [pixel2/s2]) features were
mathematically calculated from the movement of the beating syncytia
[32,38]. When compared to control cells, the analysis showed that
differentiated cardiomyocytes exposed to L55P-TTR maintained un-
altered (p > 0.05) kinematics and dynamics properties. However,
upon exposure to L55P-TTR-S-Hcy, the cardiomyocytes displayed a
significant increase (p < 0.05) of beat frequency, contraction force and
kinetic energy (1.3, 1.3-, and 1.25-fold, respectively), while retaining
substantially unaltered contractility (Fig. 6), in agreement with the
increased intracellular Ca2+. These data are of interest; in fact, they
suggest that functional correlates to the calcium-toxicity relation of
aged L55P-Hcy do exist, supporting the idea that S-homocysteinylation
of L55P-TTR resulting from hyperhomocysteinemia can be cardiotoxic
in FAC and FAP.
4. Discussion
Both genetic and environmental factors contribute to the patho-
genesis of complex diseases such as amyloid disease. The TTR amyloi-
dosis include genetically determined pathologies such as familial
amyloid polyneuropathy (FAP), including forms with heavy heart in-
volvement (FAC), and the most represented sporadic forms with heart
involvement (SSA). All these conditions are characterized by the pre-
sence of amyloid deposits in the heart and other tissues of TTR, either
containing one out of a number of described mutations, or wild type,
respectively; in particular, the L55P variant is mostly involved in car-
diac dysfunction. Recent data have reported that the thiol group of
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Cys10 found in monomeric TTR is remarkably reactive and that its
oxidation is involved in TTR tetramer destabilization [39,40]. These
findings agree with the severe oxidative stress observed in FAP patients
[14]. In addition to oxidation, other post-translational modification
modify tetramer stability. For instance, S-cysteinylation of Cys10 de-
stabilizes TTR [40,41], whereas S-sulfonation stabilizes TTR against
aggregation under acidic conditions and at pH 9 [41].
Hyperhomocysteinemia is considered as an independent risk factor
for cardiovascular disease and an emerging risk factor for cognitive
dysfunction in Alzheimer's disease [1]. Taking into account that high
Hcy levels can initiate and speed atherosclerosis, that amyloid TTR
accumulates in the heart, and that TTR can undergo S-homo-
cysteinylation at its Cys10 residue both in vitro and in vivo [18], we
investigated the effects of TTR S-homocysteinylation in terms of protein
stabilization/destabilization, propensity to undergo amyloid aggrega-
tion and toxicity of the resulting aggregates. It has been reported that in
Fig. 4. L55P-TTR S-homocysteinylation increases tetramer instability and protects against toxic HypF-N oligomers. (A) Aggregation traces of L55P-TTR and L55P-
TTR-S-Hcy, obtained by turbidimetry, (B) TEM micrographs of L55P-TTR and L55P-TTR-S-Hcy after 96 h, total and supernatant fraction obtained after centrifugation
at 14000 rpm for 30min at 4 °C. (C) Concentration dependence of L55P-TTR-S-Hcy toxicity. (D) MTT assay on HL-1 cells treated with 12 μM toxic HypF-N oligomers
(Oligo) pre-treated for 1 h with cell medium in the absence or in the presence of 1.2 μM L55P-TTR incubated for 30min or 96 h alone (L55P-TTR 30min, L55P-TTR
96 h) or with Hcy (L55P-TTR-S-Hcy 30min, L55P-TTR-S-Hcy 96 h). Error bars indicate the standard deviation of independent experiments carried out in triplicate. t-
student analysis: * p < 0.005; ** p < 0.001; ***p < 0.0001 vs control; °p < 0.005; °°p < 0.001; °°°p < 0.0001 vs Oligo. The data shown are representative of
three independent experiments.
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patients affected by homocysteinuria, total homocysteine levels can
easily raise up to 400–500 μM. However, in plasma of patients, about
70% of total Hcy is bound to protein cysteine residues via disulfide-
bond, and only 30% is in a free form [42,43]. Moreover, the “soluble
fraction” of homocysteine includes homocystine, and different types of
mixed disulfides including homocysteine-cysteine, and homocysteine-
glutathione, while the reduced free form of homocysteine does not
exceed 2% of total homocysteine content [44]. This finding suggests
that the fraction of homocysteine able to reacts with TTR is very low,
raising the question whether TTR can realistically undergo homo-
cysteinylation in vivo. Lim and co-workers reported that in a patient
suffering end-stage renal disease, with total Hcy concentration of
20.7 μM, a very small amount of S-homocysteinylated TTR was detected
[19]. Conversely, most of TTR isolated from plasma resulted S-homo-
cysteinylated in homocystenuric patients showing a total Hcy con-
centration of 434 μM [19]. Based on this evidence, we used 10 μM re-
duced Hcy to perform our tests, confiding that such concentration was
in the range of that detectable in patients affected by homocysteinuria
[45].
The data presented in this study confirmed that TTR is S-homo-
cysteinylated in vitro and this covalent modification stabilizes the tet-
rameric structure of wt-TTR while destabilizes the L55P-TTR tetramer,
thereby favouring the accumulation of toxic monomeric species.
Considering recent data indicating that monomeric TTR inhibits Aβ
peptide aggregation and amyloid plaque formation both in vitro and in
vivo [46,47], we also checked the presence of monomeric species
arising from L55P-TTR S-homocysteinylation by analysing the residual
chaperone ability of the S-homocysteinylated samples. Our in vitro
analysis showed that monomeric L55P-TTR-S-Hcy reduces the cyto-
toxicity of preformed oligomers grown from HypF-N, similarly to the
previously reported chaperonic activity of M-TTR [35,36]. Taken to-
gether, our findings suggest that S-homocysteinylation of L55P-TTR
promotes the appearance of monomeric species with higher tendency to
chaperone, as well as the M-TTR, toxic amyloid oligomers. In agree-
ment with the different tetramer stability, native and S-homo-
cysteinylated L55P-TTR exhibited different cytotoxicity to cultured
cardiac cells. We found that the viability of cardiomyocytes exposed to
L55P-TTR was affected by protein S-homocysteinylation only in the
case of 96 h-aged samples, whereas 30min-aged assemblies were
harmless. Cytotoxicity also matched the intracellular Ca2+ levels in the
same cells. In fact, we found significantly increased intracellular Ca2+
levels only in cells exposed to 96 h-aged L55P-TTR-S-Hcy, further as-
sociating cell viability impairment to the rise of intracellular Ca2+. The
toxic effects displayed by 96 h-aged L55P-TTR-S-Hcy have functional
consequences; in fact, when exposed to this sample, beating syncytia,
obtained from the differentiation of R1 mouse embryonic stem cells
showed altered kinematics and dynamics parameters. Beat frequency
(chronotropic), contraction force (inotropic) and kinetic energy (ergo-
tropic) were increased, possibly due to the impaired intracellular Ca2+
levels, whereas contractility, which represents the maximum contrac-
tion velocity, a parameter not expected to be heavily affected by Ca2+
levels, was unaltered. We did not check wt-TTR-S-Hcy cytotoxicity
since we found that the chemical modification resulted in tetramer
stabilization with maintenance of the native fold.
Different hypotheses have been proposed to describe the patholo-
gical features associated with hyperhomocysteinemia in humans;
however, the cause of Hcy toxicity is not fully understood. In this sense,
it has been proposed that accumulation of homocysteinylated proteins
is an important risk factor for cardiovascular and neurodegenerative
Fig. 5. Cytotoxicity of L55P-TTR-S-Hcy. (A) MTT assay on HL-1 cells treated
with 5 μM L55P-TTR incubated alone or with 10 μM Hcy for 30min or 96 h. (B)
Intracellular Ca2+ levels. (C) Time course of intracellular Ca2+ levels. Error
bars indicate the standard deviation of independent experiments carried out in
triplicate. t-student analysis: * p < 0.005; ** p < 0.001; ***p < 0.0001.
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diseases. In this paper, we report that S-homocysteinylation can stabi-
lize the native conformation of wt-TTR, while favouring destabilization
of L55P-TTR that by itself is considered the causative agent of a form of
early-onset familial amyloid polyneuropathy (FAP) and cardiomyo-
pathy (FAC). Our results could have pathophysiological relevance,
contributing to shed light into the molecular mechanisms underlying
some pathological consequences described in patients affected by hy-
perhomocysteinemia.
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